A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged greater than or equal to 6 Months to less than 18 Years.

Trial Profile

A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged greater than or equal to 6 Months to less than 18 Years.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Influenza virus vaccine (Afluria) (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors CSL; Seqirus
  • Most Recent Events

    • 24 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Sep 2009 Actual patient number (1992) added as reported by ClinicalTrials.gov.
    • 17 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top